Literature DB >> 24043915

Management of otolaryngological manifestations in mucopolysaccharidoses: our experience.

M Mesolella1, M Cimmino, E Cantone, A Marino, M Cozzolino, R Della Casa, G Parenti, M Iengo.   

Abstract

Mucopolysaccharidoses (MPSs) are lysosomal storage disorders caused by deficiency of enzymes involved in the degradation of glycosaminoglycans (GAGs). These disorders are associated with the accumulation of GAGs in tissues with organomegaly, mental retardation and short stature. Otologic and upper respiratory tract pathologies are among the earliest clinical manifestations. We analyzed 20 patients (13 male and 7 female, median age at the beginning of the observation 6 years) with MPS (35% type I, 30% type II, 20% type III, 5% type IV, 10% type VI), focusing on their otorhinolaryngologic problems and the impact of surgery on quality of life. We found ear, nose and throat manifestations in all types of MPS; in particular, recurrent otitis media was present in 30% of cases, hearing loss in 75% (mixed in 43.33%, conductive in 43.33%, sensorineural in 13.33%), adenotonsillar hypertrophy in 75%, frequent infections of the upper airway in 75% and obstructive sleep apnoea syndrome in 45% of cases. Fifty percent of patients required surgical therapy (adenotonsillectomy, adenoidectomy with insertion of middle ear ventilation tubes, tonsillectomy, tracheotomy and exeresis of vocal cord polyps). In our experience the ENT surgery reduced the frequency and severity of ear infections and relieved symptoms related to upper airway obstruction, thereby improving the quality of life in affected patients.

Entities:  

Keywords:  Adenotonsillectomy; Mucopolysaccharidoses; Obstructive sleep apnoea syndrome

Mesh:

Year:  2013        PMID: 24043915      PMCID: PMC3773966     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


Introduction

Mucopolysaccaridoses (MPSs) are a heterogeneous group of autosomal-recessive lysosomal storage disorders (except for MPS II, which is X-linked-recessive) characterized by deficiency of one of the lysosomal enzymes involved in the breakdown of glycosaminoglycans (GAGs). Seven types of one enzymatic defects have been described to date . This metabolic block leads to the accumulation of GAGs in lysosomes, resulting in cell, tissue and organ dysfunction . The ubiquitous nature of GAGs in the body's connective tissues gives rise to a wide phenotypic spectrum usually characterized by coarse facial features, liver and spleen enlargement, bone deformities with subsequent reduction of joint mobility, variable mental retardation and cardiac and ophthalmologic involvement . Ear, nose and throat (ENT) disorders are extremely frequent, mostly in MPS I, II and VI, and are often the earliest clinical manifestations of these diseases . Indeed, MPS patients display an increased risk of otitis media with effusion (OME) due to the pathologic deposition of GAGs in the post-nasal space, eustachian tubes and middle ear . Sensorineural hearing loss, whose aetiology remains unclear, is believed to result from infiltration of the cochlear duct, stria vascularis and cochlear nerve afferents . Nevertheless, in most MPS VI patients deficits are conductive in nature . Other common ENT disorders are: adenotonsillar hypertrophy, almost universal in MPS , chronic recurrent rhinitis and persistent copious nasal discharge . These conditions, in addition to nasal dysmorphism, mandibular abnormalities, tracheomalacia, thickened vocal cords, macroglossia and redundant tissue in the upper airway (UA) can contribute to UA complications and to obstructive sleep apnoea (OSA) -. Although patients with MPS may improve airway obstruction with more conservative treatment approaches including positive airway pressure devices (CPAP/BIPAP), management often requires early adenotonsillectomy and in extreme cases tracheostomy to ensure a patent airway in the short- or long-term . Before the advent of haematopoietic stem cell transplantation (HSCT) and especially enzyme replacement therapy (ERT), the main focus of treatment of MPS I, II, and VI was prevention and management of complications. Recently, much progress has been achieved in the treatment of MPS, and HSCT has been used in patients with MPS to correct the enzyme deficiency. Although many studies reveal that HSCT can change the natural course of the disease, increasing life expectancy and improving many systemic abnormalities , it is a high-risk procedure with high morbidity/ mortality. Moreover, its indication depends on the type of MPS, patient's clinical picture, age and presence of neurological impairment -. ERT, currently considered an efficient therapeutic method, is based on the periodic replacement of the defective enzyme, leading to higher GAG degradation in tissues and organs and promoting significant improvement in some clinical features. However, the influence of ERT on pathological manifestations is still not well understood, and long-term data on its efficacy is not yet available . We designed an observational study in order to define the incidence of ENT problems in patients with MPSs and to establish the impact of surgical treatment. We also observed the role of surgery in improving the clinical phenotype and the quality of life of patients affected by MPSs.

Material and methods

The present study includes 20 patients with MPS (7 [35%] MPS I, 6 [30%] MPS II, 4 [20%] MPS III, 1 [5%] MPS IV and 2 [10%] MPS VI), 13 male and 7 female (median age at the beginning of the observation 6 years, ranging from 1 to 16), observed at the Department of Paediatric Medicine of Federico II University in Naples from June 1999 to June 2009. The median age at diagnosis of MPS was 3 years and the median age of presentation to an otolaryngologist was 12 months. The average length of follow-up was 8.4 years. We performed flexible fibre otoscopy, rhinopharyngolaryngoscopy, tympamograms, audiograms in patients able to cooperate (n = 15) in addition to polysomnography. The following was considered: The number of OME and upper respiratory tract infections (URTIs) episodes per year. Adenoid hypertrophy (Grade 1: adenoid tissue occupies only the upper segment in the rhinopharyngeal cavity; Grade 2: adenoid tissue is confined to the upper half of the rhinopharyngeal cavity; Grade 3: adenoid tissue is extended over the rhinopharynx with obstruction of choanal openings and partial closure of tube ostium; Grade 4: tube ostium and lower choanal border could not be observed) . Tonsillar hypertrophy (0: tonsils entirely within the tonsillar fossa; 1: tonsils occupying less than 25% of the lateral dimension of the oropharynx as measured between the anterior tonsillar pillars; 2: tonsils occupying less than 50% of the lateral dimension of the oropharynx; 3: tonsils occupying less than 75% of the lateral dimension of the oropharynx; 4: tonsils occupying 75% or more of the lateral dimension of the oropharynx). Audiometric test. Type of tympanograms (Type A: static compliance [SA] ≥ 0.2 cm3, tympanic peak pressure [TPP] -200 → +100 mm H2O, type B: SA < 0.2 cm3, type C: SA ≥ 0.2 cm3, TPP ≤ 200 mm H2O). OSAS (number of obstructive apnoea and hypopnoea events per hour of sleep: apnoea-hypopnoea index AHI and oxygen saturation: Sat % O2). Eight (40%) of our patients (3 MPS I, 4 MPS II and 1 MPS VI) were treated with ERT; of these, 4 patients (1 MPS I, 2 MPS II and 1 MPS VI) underwent surgery, in 2 cases before starting enzyme therapy and in the remaining 2 cases one year after initiating therapy. In 10 patients (50%) surgical therapy was required (Table I): adenotonsillectomy in 5 patients (25%), adenoidectomy in 3 patients (15%), tonsillectomy in 2 patients (10%), insertion of middle ear ventilation tubes in 3 patients (15%), tracheotomy in 1 patient (5%) and exeresis of vocal cord polyps in 1 patient (5%). Flexible fibre-optic laryngoscopy was performed before surgery to familiarize the anaesthesiologist with the anatomy that would be encountered.
Table I.

Surgical procedures performed.

Patients1568111214161920
AdenoidectomyXXX
Tonsillectomy X X
Adenotonsillectomy XXXX X
Insertion of middle ear ventilation tubesX X X
TracheotomyX
Exeresis of polyps of the vocal cords X
Surgical procedures performed. We finally considered the role of ENT surgery on improvement in quality of life, estimated through parental opinion and clinical manifestations. In particular, the severity of respiratory tract and/or otological infections was evaluated according to an infection score system considering the type of infection, presence of systemic symptoms, impairment of daily activities, improvement of instrumental date, need for therapy and/or hospital admission and duration of disease (Table II).
Table II.

Total score ≤ 5: mild respiratory tract and/or otological infection; score 6-11: moderate respiratory tract and/or otological infection; score ≥ 12: severe respiratory tract and/or otological infection.

Score
Type of infectionRhinitis0
Rhinitis + otitis and/or tonsillitis1
Pneumonia2
Systemic symptomsAbsent0
Slight fever and/or some aches1
Definite elevation of temperature2
Daily activityNot limited0
Some limitation1
Severely incapacitated2
TherapyLocal0
Systemic (oral administration)1
Systemic (intravenous administration)2
HospitalizationNo0
Single entry followed by home therapy1
Admission2
Resolution< 7 days0
7-10 days1
> 10 days2
Total score ≤ 5: mild respiratory tract and/or otological infection; score 6-11: moderate respiratory tract and/or otological infection; score ≥ 12: severe respiratory tract and/or otological infection. A visual analogue scale (VAS) is a psychometric response scale used for subjective characteristics or attitudes that cannot be directly measured. A VAS is usually a horizontal line, 10 cm in length, anchored by picture descriptors. Patients indicate the line point that they feel best represents perception of their current state (pain, ability to do daily activity) before and after surgery.

Results

18 of 20 patients (90%) showed at least one ENT manifestations (Table III). In particular, 6 patients (30%) had a history of chronic and recurrent OME ≥ 5 episodes in a year. Hearing loss was demonstrated by audiogram and ABR in 15/20 (75%) patients: in 6 (43.33%) patients mixed hypoacusia was present, conductive hypoacusia in 6 (43.33%) and sensorineural hypoacusia in 3 (13.33%) cases. We found type A tympanograms in 6 patients, type B in 10 and type C in 4 patients. Adenoid hypertrophy (degree ≥ 2) was present in 15 of 20 (75%) cases; tonsillar hypertrophy (degree ≥ 1) was present in 17 of the 20 patients; UA obstruction and OSA was present in 8 cases. 15 patients (75%) had a history of URTIs, such as rhinosinusitis, pharyngotonsillitis and laryngitis. In 9 patients (45%), OSA was documented by positive results of polysomnnography that demonstrated apnoea-hypopnea indexes (AHI) ranging from 18 to 31, and an oxygen saturation ranging from 74% to 85%.
Table III.

Otorhinolaryngological manifestations.

PtMPSOtitis media No. of episodes per yearHypoacusiaTympanogramsDegree adenoid hypertrophyDegree tonsillar hypertrophy(URTIs) No. of episodes per yearOSAS AHI
1I7ConductiveB42631
2I2MixedC215
3I2MixedB215
4I2SensorineuralA215
5I H/S6ConductiveB32622
6I S3MixedB326
7I0SensorineuralA202
8II3MixedC13525
9II1-A203
10II2SensorineuralA225
11II4MixedB33628
12II6ConductiveB44729
13II2-C115
14III B7ConductiveB33618
15III B0-A12219
16III B7ConductiveB43726
17III B1-A102
18IV A1-C213
19VI3MixedB136
20VI8ConductiveB33721
Otorhinolaryngological manifestations. Ten patients underwent surgical treatment, and none required prolonged intubation. Figure 1 shows the comparison between ENT manifestations before and after surgery.
Fig. 1.

Comparison between otorhinolaryngological manifestations before and after surgery.

Comparison between otorhinolaryngological manifestations before and after surgery. At least 30% (3 patients) of the patients obtained an improvement in quality of life. Indeed, VAS scores after surgery compared to VAS score before surgery significantly improved (median value 7.0 ± 1.5 vs. 3.6 ± 1.6). The severity of respiratory and ENT infections, measured with the infection score system also showed improvement (median infection score before surgery 13.7 ± 4.6 vs. 3.9 ± 2.4 after surgery). One patient (10%) still presented OSA after adenotonsillectomy because of macroglossia and dysmorphism. All patients are still alive at the time of writing.

Discussion

MPSs are lysosomal storage disorders with deficiency of enzymes involved in the degradation of GAGs. The structures of the head and neck are nearly always involved in MPSs, often at an early age, and as a result, otolaryngologists are commonly the first clinicians to whom these individuals present. Our study confirms the importance of ENT management in the multidisciplinary approach to these patients. Because of the high incidence of ear disorders, and their effects on language development and quality of life, routine otologic and audiologic evaluation must be obtained . Hearing loss affects almost all MPS patients, which is characterized by both conductive and sensorineural involvement. In fact, in the present study, hearing loss was present in 75% of cases, in agreement with literature data, in which the percentage varies from 59.7% to 89% . While it is reported that conductive hearing loss can be improved after adenoidectomy and insertion of middle ear ventilation tubes , amplification is typically required to overcome what is generally permanent sensorineural loss. As mentioned above, our data confirm these observations as about 60% of cases experienced improvement in hearing after surgical treatment. While otologic manifestations have an effect on quality of life, upper-airway obstruction contributes more to morbidity and mortality. The accumulation of mucopolysaccharides can cause alterations of normal airway function, so prompt diagnosis is crucial. Changes in soft tissues including tonsils, adenoids, tongue and lingual tonsils are responsible for most respiratory problems. As the disease progresses, pharyngomalacia and tracheomalacia may develop and become severe, leading to significant airway obstruction . Upper airway obstruction may range from varying degrees of OSA to life-threatening airway emergencies. However, airway evaluation is very difficult, typically non-uniform among different providers and varies from case to case . In the present study, we found upper airway obstruction in 75% of cases while literature data describes percentages varying from 38% to 48% to 92% . Currently, treatment of airway obstruction is controversial, but the accumulation of GAGs in the adenoids and tonsils, with resulting hypertrophy, makes these structures frequent targets of surgical intervention. Therefore, in more severe forms, such as purulent, recurrent and chronic cases, adenoidectomy should be performed without delay . OSA initially can be helped by tonsillectomy and adenoidectomy, but many patients require nocturnal oxygen treatment later or, in more severe cases, tracheotomy. In the light of the elevated anaesthetic risk of this population due to copious secretions, temporomandibular joint arthritis, difficult or failed intubations, macroglossia, abnormal laryngeal anatomy and subglottic narrowing , in our centre, it is common practice to perform and record a bronchoscopy examination with a flexible fibre-optic bronchoscope before surgery to evaluate the extent and severity of airway infiltration. Among 20 MPS patients, 10 (50%) underwent surgery (Table I): adenotonsillectomy (5 patients, 25%), adenoidectomy (3 patients, 15%), tonsillectomy (2 patients, 10%), insertion of middle ear ventilation tubes (3 patients, 15%), tracheotomy (1 patient, 5%) and exeresis of vocal cord polyps (1 patient, 5%). OSA evaluation should begin with history and physical examination, but the degree of pre and post-operative obstruction should be studied with polysomnography and rhino-oro-laryngoscopy . For these reasons, we performed a pre- and post-operative sleep study that demonstrated improvement of AHI ranging from 7 to 15 after surgery, with oxygen saturation ranging from 81% to 87% compared to preoperative results (AHI ranging from 18 to 31, and oxygen saturation ranging from 74% to 85%). One patient (10%), in contrast, still presented OSA after adenotonsillectomy because of his macroglossia and dysmorphism. The study was also designed to examine the quality of life of patients affected by MPSs using a VAS score, measured before and after surgery, which demonstrated a significant improvement after treatment from score 5 (60%) and score 4 (40%) to score 3 (75%) and score 2 (25%).

Conclusions

In conclusion, because of the high incidence of ENT manifestations in MPS, otolaryngologists have a crucial role in the multidisciplinary approach to diagnosis and management of many subjects with this disorder. Moreover, despite the fact that ERT has made an important contribution to improving the quality of life of these patients, ENT surgery remains a fundamental therapeutic procedure for reducing the frequency and severity of ear infections and for relieving the symptoms of upper airway obstruction, even if these interventions are not definitive.
  23 in total

Review 1.  Management guidelines for mucopolysaccharidosis VI.

Authors:  Roberto Giugliani; Paul Harmatz; James E Wraith
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

Review 2.  The clinical outcome of Hurler syndrome after stem cell transplantation.

Authors:  Mieke Aldenhoven; Jaap Jan Boelens; Tom J de Koning
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

Review 3.  The mucopolysaccharidoses: a clinical review and guide to management.

Authors:  J E Wraith
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

4.  Bone marrow transplantation in Hunter syndrome.

Authors:  E J McKinnis; S Sulzbacher; J C Rutledge; J Sanders; C R Scott
Journal:  J Pediatr       Date:  1996-07       Impact factor: 4.406

5.  Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings.

Authors:  F Santamaria; M V Andreucci; G Parenti; M Polverino; D Viggiano; S Montella; A Cesaro; R Ciccarelli; B Capaldo; G Andria
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

Review 6.  Multidisciplinary management of Hunter syndrome.

Authors:  Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith
Journal:  Pediatrics       Date:  2009-11-09       Impact factor: 7.124

7.  The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review.

Authors:  M J Ruckenstein; R E Macdonald; J T Clarke; V Forte
Journal:  J Otolaryngol       Date:  1991-06

Review 8.  Insights into the diagnosis and treatment of lysosomal storage diseases.

Authors:  David A Wenger; Stephanie Coppola; Shu-Ling Liu
Journal:  Arch Neurol       Date:  2003-03

9.  Airway management in children with mucopolysaccharidoses.

Authors:  Andrea H Yeung; Morton J Cowan; Biljana Horn; Kristina W Rosbe
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-01

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  9 in total

Review 1.  Sleep-disordered breathing in paediatric setting: existing and upcoming of the genetic disorders.

Authors:  Marco Zaffanello; Franco Antoniazzi; Laura Tenero; Luana Nosetti; Michele Piazza; Giorgio Piacentini
Journal:  Ann Transl Med       Date:  2018-09

2.  Hyoid myotomy without suspension: a surgical approach to obstructive sleep apnoea syndrome.

Authors:  E Scarano; G Della Marca; E De Corso; S Dittoni; W Di Nardo; D Meucci; G Bastanza; R Gallus; A Losurdo; E Testani; G Paludetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-10       Impact factor: 2.124

Review 3.  ENT and mucopolysaccharidoses.

Authors:  Pier Marco Bianchi; Renato Gaini; Silvano Vitale
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

4.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

Review 5.  Report on advances for pediatricians in 2018: allergy, cardiology, critical care, endocrinology, hereditary metabolic diseases, gastroenterology, infectious diseases, neonatology, nutrition, respiratory tract disorders and surgery.

Authors:  Carlo Caffarelli; Francesca Santamaria; Carla Mastrorilli; Angelica Santoro; Brunella Iovane; Maddalena Petraroli; Valeria Gaeta; Rosita Di Pinto; Melissa Borrelli; Sergio Bernasconi; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2019-10-16       Impact factor: 2.638

6.  Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.

Authors:  Kyoko Nagao; Thierry Morlet; Elizabeth Haley; Jennifer Padilla; Julianne Nemith; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-02-08       Impact factor: 4.204

Review 7.  Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

Authors:  Jeremy Wolfberg; Keerthana Chintalapati; Shunji Tomatsu; Kyoko Nagao
Journal:  Diagnostics (Basel)       Date:  2020-08-04

Review 8.  Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses.

Authors:  Miriam Rigoldi; Elena Verrecchia; Raffaele Manna; Maria Teresa Mascia
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

9.  Otorhinolaryngological Management in Taiwanese Patients with Mucopolysaccharidoses.

Authors:  Chung-Lin Lee; Kuo-Sheng Lee; Chih-Kuang Chuang; Chin-Hui Su; Huei-Ching Chiu; Ru-Yi Tu; Yun-Ting Lo; Ya-Hui Chang; Hsiang-Yu Lin; Shuan-Pei Lin
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.